PL357499A1 - Leczenie rozedmy płuc z zastosowaniem selektywnych antagonistów retynoidów RAR - Google Patents

Leczenie rozedmy płuc z zastosowaniem selektywnych antagonistów retynoidów RAR

Info

Publication number
PL357499A1
PL357499A1 PL00357499A PL35749900A PL357499A1 PL 357499 A1 PL357499 A1 PL 357499A1 PL 00357499 A PL00357499 A PL 00357499A PL 35749900 A PL35749900 A PL 35749900A PL 357499 A1 PL357499 A1 PL 357499A1
Authority
PL
Poland
Prior art keywords
emphysema
treatment
retinoid antagonists
selective rar
rar retinoid
Prior art date
Application number
PL00357499A
Other languages
English (en)
Polish (pl)
Inventor
Paula Nanette Belloni
Michael Klaus
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL357499A1 publication Critical patent/PL357499A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL00357499A 1999-10-19 2000-10-13 Leczenie rozedmy płuc z zastosowaniem selektywnych antagonistów retynoidów RAR PL357499A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Publications (1)

Publication Number Publication Date
PL357499A1 true PL357499A1 (pl) 2004-07-26

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00357499A PL357499A1 (pl) 1999-10-19 2000-10-13 Leczenie rozedmy płuc z zastosowaniem selektywnych antagonistów retynoidów RAR

Country Status (33)

Country Link
US (1) US6300350B1 (OSRAM)
EP (1) EP1225878B1 (OSRAM)
JP (2) JP4074458B2 (OSRAM)
KR (1) KR100485581B1 (OSRAM)
CN (1) CN1201730C (OSRAM)
AR (1) AR029648A1 (OSRAM)
AT (1) ATE344661T1 (OSRAM)
AU (1) AU777325B2 (OSRAM)
BR (1) BR0015225A (OSRAM)
CA (1) CA2387844C (OSRAM)
CY (1) CY1105941T1 (OSRAM)
CZ (1) CZ20021657A3 (OSRAM)
DE (1) DE60031790T2 (OSRAM)
DK (1) DK1225878T3 (OSRAM)
ES (1) ES2274810T3 (OSRAM)
HR (1) HRP20020329A2 (OSRAM)
HU (1) HUP0203295A3 (OSRAM)
IL (1) IL149151A0 (OSRAM)
JO (1) JO2178B1 (OSRAM)
MA (1) MA26835A1 (OSRAM)
MX (1) MXPA02003843A (OSRAM)
MY (1) MY129001A (OSRAM)
NO (1) NO328738B1 (OSRAM)
NZ (1) NZ518118A (OSRAM)
PE (1) PE20010678A1 (OSRAM)
PL (1) PL357499A1 (OSRAM)
PT (1) PT1225878E (OSRAM)
RS (1) RS50165B (OSRAM)
RU (1) RU2257383C2 (OSRAM)
TR (1) TR200201071T2 (OSRAM)
TW (1) TWI288639B (OSRAM)
WO (1) WO2001030326A1 (OSRAM)
ZA (1) ZA200202576B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
KR100891224B1 (ko) 2001-09-18 2009-04-01 에프. 호프만-라 로슈 아게 치환된 우레아 레티노이드 작용제 ⅱ
CN1283621C (zh) * 2001-09-18 2006-11-08 霍夫曼-拉罗奇有限公司 烷基脲的类维生素a激动剂ⅰ
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20070042184A1 (en) 2003-08-22 2007-02-22 Danisco A/S Microcapsules
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
EP2394647A1 (en) * 2006-11-02 2011-12-14 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
EP4066826B1 (en) 2010-09-01 2024-03-06 Thomas Jefferson University Retinoic acid receptor gamma agonists for muscle repair and regeneration
US9949996B2 (en) 2011-06-24 2018-04-24 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US20140155381A1 (en) * 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
SI2931713T1 (sl) 2012-12-17 2017-03-31 Parion Sciences, Inc. Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice
ES2909884T3 (es) 2013-08-20 2022-05-10 Univ Washington Through Its Center For Commercialization Inhibidores nuevos y específicos de la hidroxilasa del ácido retinoico del citocromo P450 26
WO2015041809A2 (en) 2013-08-26 2015-03-26 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
US5824682A (en) * 1993-08-18 1998-10-20 Janssen Pharmaceutica, N.V. Vasoconstrictive dihydrobenzopyran derivatives
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
EP0728742B1 (en) * 1995-02-24 1999-10-20 F. Hoffmann-La Roche Ag Novel retinoids
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
BR9814957A (pt) * 1997-11-12 2000-10-03 Hoffmann La Roche Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
CN1166618C (zh) * 1999-08-02 2004-09-15 霍夫曼-拉罗奇有限公司 新型选择性视黄醛激动剂
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
RU2257383C2 (ru) 2005-07-27
AU777325B2 (en) 2004-10-14
TR200201071T2 (tr) 2002-08-21
CA2387844A1 (en) 2001-05-03
PE20010678A1 (es) 2001-07-04
CZ20021657A3 (cs) 2002-10-16
JP2007302689A (ja) 2007-11-22
HUP0203295A2 (hu) 2003-01-28
IL149151A0 (en) 2002-11-10
NZ518118A (en) 2004-02-27
MY129001A (en) 2007-03-30
MA26835A1 (fr) 2004-12-20
TWI288639B (en) 2007-10-21
BR0015225A (pt) 2002-07-16
YU29002A (sh) 2005-06-10
NO20021823L (no) 2002-04-18
DE60031790D1 (de) 2006-12-21
US6300350B1 (en) 2001-10-09
CN1201730C (zh) 2005-05-18
ES2274810T3 (es) 2007-06-01
ZA200202576B (en) 2003-09-23
EP1225878A1 (en) 2002-07-31
MXPA02003843A (es) 2002-09-30
CA2387844C (en) 2009-04-14
JP2003512418A (ja) 2003-04-02
HK1051002A1 (zh) 2003-07-18
PT1225878E (pt) 2007-01-31
CY1105941T1 (el) 2011-04-06
RS50165B (sr) 2009-05-06
DK1225878T3 (da) 2007-03-05
ATE344661T1 (de) 2006-11-15
JP4074458B2 (ja) 2008-04-09
AR029648A1 (es) 2003-07-10
HRP20020329A2 (en) 2004-04-30
JO2178B1 (en) 2003-04-23
JP4850791B2 (ja) 2012-01-11
NO328738B1 (no) 2010-05-03
EP1225878B1 (en) 2006-11-08
AU1137401A (en) 2001-05-08
CN1382042A (zh) 2002-11-27
KR20020043640A (ko) 2002-06-10
KR100485581B1 (ko) 2005-04-27
NO20021823D0 (no) 2002-04-18
WO2001030326A1 (en) 2001-05-03
DE60031790T2 (de) 2007-09-20
HUP0203295A3 (en) 2003-04-28

Similar Documents

Publication Publication Date Title
FI20000863L (fi) Uusi hoitomenetelmä
ATE324009T1 (de) Verfahren und systeme zum aufbau von benutzermedialisten
PL357499A1 (pl) Leczenie rozedmy płuc z zastosowaniem selektywnych antagonistów retynoidów RAR
DE60120276D1 (de) Laserbehandlungsgerät
DE60105229D1 (de) Laserbehandlungsgerät
DE60026169D1 (de) Selektive neurokinin-antagonisten
DE60017514D1 (de) Laserbehandlungsgerät
NO20014950D0 (no) Nye behandlingsmetoder
FI19992171A7 (fi) Sprinkleri
DE60121531D1 (de) Laserbehandlungsgerät
NO20040353L (no) Ny terapeutsk metode
DE60100737D1 (de) Laserbehandlungsgerät
DK1226131T3 (da) Isoxazolcarboxamidderivater
DE60128018D1 (de) Objektüberwachungsvorrichtung
NO20022564D0 (no) Nye androgener
NO20013337D0 (no) Ny behandling
DE50312878D1 (de) Mikrowellen-Pulsgenerator
DE60112167D1 (de) Vibrator
ID30381A (id) Penggunaan arilalkanoilpiridazina
IS6626A (is) Kristallskenndur meðferðarmiðill
DK1135128T3 (da) Nye behandlingsfremgangsmåder
ATA114799A (de) Abseilgerät
FI990084L (fi) Kentänohjain
FI4745U1 (fi) Valvontalaitteisto
FI20002756A0 (fi) Uusi hoitomenetelmä

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)